Drug Safety:澳大利亚老年人不良药物反应相关的住院治疗

2017-07-06 MedSci MedSci原创

不良药物反应(ADRs)通常被认为是老年人住院的主要原因。然而,尽管这个问题是非常明确的,但目前关于其的前瞻性数据有限。近日,国际杂志 《Drug Safety》上在线发表一项关于澳大利亚老年人不良药物反应相关住院治疗的两个塔斯马尼亚医院的前瞻性跨部门研究。

不良药物反应(ADRs)通常被认为是老年人住院的主要原因。然而,尽管这个问题是非常明确的,但目前关于其的前瞻性数据有限。近日,国际杂志 《Drug Safety》上在线发表一项关于澳大利亚老年人不良药物反应相关住院治疗的两个塔斯马尼亚医院的前瞻性跨部门研究。

该研究的目的是评估入住两家塔斯马尼亚医院的老年患者ADR相关入院的比例,临床特征,因果关系,严重程度,可预防性和预后。

研究人员在澳大利亚塔斯马尼亚的皇家霍巴特和朗塞斯顿综合医院进行了一项前瞻性横断面研究。筛查65岁及以上无计划住院病人样本。通过对医疗记录和患者访谈的详细调查,经专家共识确定相关的ADR入院。评估每个ADR相关入院的因果关系,可预防性和严重程度。

1008次入院中,潜在的ADR相关入院比例为18.9%。大多数(88.5%)与ADR相关的入院被认为是可预防的。最常见的ADR为心血管疾病(29.3%),其次是神经精神病学(20.0%),肾脏和泌尿生殖系统疾病(15.2%)。最常涉及的药物类别是利尿剂(23.9%),作用于肾素血管紧张素系统的药剂(16.4%),β受体-阻断剂(7.1%),抗抑郁药(6.9%)和抗血栓剂(6.9%)。Naranjo算法的应用发现有5.8%的确定,70.1%的很可能和24.1%的可能的ADRADR严重程度分为中等和重度分别为97.9%和2.1%。对于大多数(93.2%)ADR相关的入院患者,ADR已经解决,患者恢复正常。

由于ADR引起的住院治疗在老年人群中常见。需要今后的研究来实施和评估干预措施,以减少老年人ADR相关入院的风险。

原始出处:

Nibu Parameswaran Nair, Leanne Chalmers, Bonnie J,et al. Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793530, encodeId=57681e9353095, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 06 14:44:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862255, encodeId=1264186225544, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jul 30 21:44:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952887, encodeId=90dd195288eff, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Mar 04 19:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483937, encodeId=14c2148393e25, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Jul 08 09:44:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219477, encodeId=e3f62194e786, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:50:46 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2017-12-06 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793530, encodeId=57681e9353095, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 06 14:44:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862255, encodeId=1264186225544, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jul 30 21:44:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952887, encodeId=90dd195288eff, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Mar 04 19:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483937, encodeId=14c2148393e25, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Jul 08 09:44:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219477, encodeId=e3f62194e786, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:50:46 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2017-07-30 爆笑小医
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793530, encodeId=57681e9353095, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 06 14:44:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862255, encodeId=1264186225544, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jul 30 21:44:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952887, encodeId=90dd195288eff, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Mar 04 19:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483937, encodeId=14c2148393e25, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Jul 08 09:44:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219477, encodeId=e3f62194e786, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:50:46 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793530, encodeId=57681e9353095, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 06 14:44:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862255, encodeId=1264186225544, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jul 30 21:44:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952887, encodeId=90dd195288eff, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Mar 04 19:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483937, encodeId=14c2148393e25, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Jul 08 09:44:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219477, encodeId=e3f62194e786, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:50:46 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1793530, encodeId=57681e9353095, content=<a href='/topic/show?id=5cc615840e7' target=_blank style='color:#2F92EE;'>#safety#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15840, encryptionId=5cc615840e7, topicName=safety)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 06 14:44:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862255, encodeId=1264186225544, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jul 30 21:44:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952887, encodeId=90dd195288eff, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Mar 04 19:44:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483937, encodeId=14c2148393e25, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Jul 08 09:44:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219477, encodeId=e3f62194e786, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Jul 07 10:50:46 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2017-07-07 Chongyang Zhang

    签到学习了很多

    0